Overview

Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate, nab-paclitaxel and S-1
Phase:
Phase 2
Details
Lead Sponsor:
Fujian Medical University
Treatments:
Apatinib
Docetaxel
Paclitaxel